Impaired diffusion capacity predicts for decreased treatment tolerance and survival in limited stage small cell lung cancer patients treated with concurrent chemoradiation

Lung Cancer

Volumn 43, Issue 2, 2004, Pages 159-166

  Videtic, Gregory M M ^a   Stitt, Larry W ^b   Ash, Robert B ^b   Truong, Pauline T ^c   Dar, A Rashid ^b   Yu, Edward W ^b   Whiston, Frances ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Chemoradiation; Diffusion capacity; Limited stage small cell lung cancer; Pulmonary function tests; Toxicity

Indexed keywords

CARBON MONOXIDE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION FIELD; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 1642534410     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.08.026     Document Type: Conference Paper

References (19)

1. Sherman C.A., Lima C.M.R., Turrisi A.T. III Limited small-cell lung cancer: a potentially curable disease. Oncology (Huntingt). 14:2000;1395-1403.
2. Murray N. Small-cell lung cancer at the millennium: radiotherapy innovations improve survival while new chemotherapy treatments remain unproven. Clin. Lung Cancer. 1:2000;181-190.
3. Murray N., Coy P., Pater J.L.et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J. Clin. Oncol. 11:1993;336-344.
4. Turrisi A.T. III, Kyungmann K., Blum R.et al. Twice-daily compare with one-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. 340:1999;265-271.
5. Goto K., Mishawaka Y., Takada M.et al. Final results of a phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage SCLC: the Japan Clinical Oncology (JCOG) study (Abstr.). Proc. Am. Soc. Clin. Oncol. 18:1999;468a.
6. Jeremic B., Shibamato Y., Acimovic L.et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited SCLC: a randomized study. J. Clin. Oncol. 15:1997;893-900.
7. Tannock IF. Experimental chemotherapy. In: Tannock IF, Hill RP, editors, The basic science of oncology. New York: McGraw-Hill, 1992. p. 338-59.
8. Videtic G.M., Fung K., Tomiak A.T.et al. Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. Lung Cancer. 33:2001;249-258.
9. Martinez FJ, Paine R III. Medical evaluation of the patient with potentially resectable lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, editors, Lung cancer: principles and practice. Philadelphia: Lippincott-Raven, 1996. p. 511-36.
10. Werner-Wasik M., Scott C., Cox J.D.et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): Identification of five groups with different survival. Int. J. Radiat. Oncol. Biol. Phys. 48:2000;1475-1482.
11. Murray N., Hadzic E., Shah A.et al. Alternating chemotherapy and thoracic irradiation with concurrent cisplatin-etoposide for limited stage SCLC. (Abstr.). proc. Am. Soc. Clin. Oncol. 3:1984;321a.
12. Turrisi A.T. III, Withers H.R. Radiotherapy in limited small cell lung cancer: fractionation and timing of modalities. Semin. Radiat. Oncol. 5:1995;55-60.
13. Abratt R.P., Morgan G.W. Lung toxicity following chest irradiation in patients with lung cancer. Radiother. Oncol. 35:2002;103-109.
14. Kadono K., Satoh H., Homma T.et al. Radiotherapy for elderly non-small cell lung cancer patients. Oncol. Rep. 9:2002;1273-1276.
15. Azimov R.I. Diffusion ability of lungs at advanced age. Adv. Gerontol. 9:2002;116-118.
16. Videtic G.M.M., Stitt L.W., Dar A.R.et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small - cell lung cancer is associated with decreased survival. J. Clin. Oncol. 21:2003;1544-1549.
17. Handy J.R., Asaph J.W., Skokan L.et al. What happens to patients undergoing lung cancer surgery? Outcomes and quality of life before and after surgery. Chest. 122:2002;21-30.
18. Ferguson M., Little L., Rizzo L.et al. Diffusion capacity predicts morbidity and mortality after pulmonary resection. J. Thorac. Cardiovasc. Surg. 69:1988;894-900.
19. Markos J., Mullan B., Hillman D.et al. Preoperative assessment of mortality and morbidity after lung resection. Am. Rev. Respir. Dis. 139:1989;902-910.